Please assess the completion status of the following clinical trial:

Trial Title: Montelukast for Patients With Obstructive Sleep Apnea Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* With mild to moderate obstructive sleep apnea syndrome (apnea / hypopnea index\> 15 and \<30 events per hour)~* Little symptomatic (Epworth sleepiness score \<10)~* Polysomnography within 3 months prior to inclusion~* With a history of myocardial infarction or stroke~* Affiliation to Social Security or beneficiary of such a scheme~* Signed consent~Exclusion Criteria:~* OSAS support by PPC~* Cancer~* Chronic inflammatory disease~* Asthma previously treated with Montelukast~* Chronic infectious disease~* Epworth sleepiness scale ≥10~* Contraindication to Montelukast: Hypersensitivity to the active substance or to the excipients~* Contraindications to trinitrin: hypersensitivity to nitrates, state of shock, severe hypotension, association with sildenafil, obstructive cardiomyopathy, inferior right sided myocardial infarction with right ventricular extension, acute, except in case of signs left ventricular failure, intracranial hypertension, breastfeeding~* Treatment with phenobarbital, phenytoin, rifampicin: risk of montelukast metabolism increase and thus decrease of its effectiveness~* Persons referred in Articles L1121-5 to L1121-8 of the CSP (pregnant woman, parturient, nursing mothers, person deprived of liberty by judicial or administrative decision, person subject to a measure of legal protection, can not be included in clinical trials)~* Subject in exclusion period of another study~* Subject can not be contacted in case of emergency

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: EXPERIMENTAL): Drug :Montelukast, capsule, 10mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
- Placebo (Type: PLACEBO_COMPARATOR): Drug: Mannitol, capsule, 350mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).